141 related articles for article (PubMed ID: 37273644)
1. Imidazopyridine Amides: Synthesis,
Abdelaziz R; Di Trani JM; Sahile H; Mann L; Richter A; Liu Z; Bueler SA; Cowen LE; Rubinstein JL; Imming P
ACS Omega; 2023 May; 8(21):19081-19098. PubMed ID: 37273644
[TBL] [Abstract][Full Text] [Related]
2. Structure of mycobacterial CIII
Yanofsky DJ; Di Trani JM; Król S; Abdelaziz R; Bueler SA; Imming P; Brzezinski P; Rubinstein JL
Elife; 2021 Sep; 10():. PubMed ID: 34590581
[TBL] [Abstract][Full Text] [Related]
3. Response of
Chauhan P; van der Meulen SA; Simões Caetano JM; Goojani HG; Botman D; van Spanning R; Lill H; Bald D
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142240
[TBL] [Abstract][Full Text] [Related]
4. Terminal Respiratory Oxidases: A Targetables Vulnerability of Mycobacterial Bioenergetics?
Bajeli S; Baid N; Kaur M; Pawar GP; Chaudhari VD; Kumar A
Front Cell Infect Microbiol; 2020; 10():589318. PubMed ID: 33330134
[TBL] [Abstract][Full Text] [Related]
5. The anti-mycobacterial activity of the cytochrome bcc inhibitor Q203 can be enhanced by small-molecule inhibition of cytochrome bd.
Lu P; Asseri AH; Kremer M; Maaskant J; Ummels R; Lill H; Bald D
Sci Rep; 2018 Feb; 8(1):2625. PubMed ID: 29422632
[TBL] [Abstract][Full Text] [Related]
6. Isolation and Characterization of a Hybrid Respiratory Supercomplex Consisting of Mycobacterium tuberculosis Cytochrome bcc and Mycobacterium smegmatis Cytochrome aa3.
Kim MS; Jang J; Ab Rahman NB; Pethe K; Berry EA; Huang LS
J Biol Chem; 2015 Jun; 290(23):14350-60. PubMed ID: 25861988
[TBL] [Abstract][Full Text] [Related]
7. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
Ceska Slov Farm; 2021; 70(5):164-171. PubMed ID: 35114793
[TBL] [Abstract][Full Text] [Related]
8. Telacebec (Q203): Is there a novel effective and safe anti-tuberculosis drug on the horizon?
Malík I; Čižmárik J; Kováč G; Pecháčová M; Hudecova L
Ceska Slov Farm; 2021; 70(5):164–171. PubMed ID: 34875838
[TBL] [Abstract][Full Text] [Related]
9. Bipolar Distribution of Minimum Inhibitory Concentration of Q203 Across Mycobacterial Species.
Wang J; Jing W; Shi J; Huo F; Shang Y; Wang F; Chu N; Pang Y
Microb Drug Resist; 2021 Aug; 27(8):1013-1017. PubMed ID: 33646044
[TBL] [Abstract][Full Text] [Related]
10. Deciphering insights into the binding mechanism and plasticity of Telacebec with
Ray B; Roy KK
J Biomol Struct Dyn; 2023 Dec; ():1-14. PubMed ID: 38111165
[TBL] [Abstract][Full Text] [Related]
11. Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.
Converse PJ; Almeida DV; Tyagi S; Xu J; Nuermberger EL
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036687
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis.
Parrish NM; Houston T; Jones PB; Townsend C; Dick JD
Antimicrob Agents Chemother; 2001 Apr; 45(4):1143-50. PubMed ID: 11257028
[TBL] [Abstract][Full Text] [Related]
13. Methylotrophy in Mycobacteria: Dissection of the Methanol Metabolism Pathway in Mycobacterium smegmatis.
Dubey AA; Wani SR; Jain V
J Bacteriol; 2018 Sep; 200(17):. PubMed ID: 29891642
[TBL] [Abstract][Full Text] [Related]
14. Insights into the Physiology and Metabolism of a Mycobacterial Cell in an Energy-Compromised State.
Patil V; Jain V
J Bacteriol; 2019 Oct; 201(19):. PubMed ID: 31285242
[No Abstract] [Full Text] [Related]
15. Design, Synthesis and Evaluation of
Zitko J; Mindlová A; Valášek O; Jand'ourek O; Paterová P; Janoušek J; Konečná K; Doležal M
Molecules; 2018 Sep; 23(9):. PubMed ID: 30231544
[TBL] [Abstract][Full Text] [Related]
16. Exploiting the synthetic lethality between terminal respiratory oxidases to kill
Kalia NP; Hasenoehrl EJ; Ab Rahman NB; Koh VH; Ang MLT; Sajorda DR; Hards K; Grüber G; Alonso S; Cook GM; Berney M; Pethe K
Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7426-7431. PubMed ID: 28652330
[TBL] [Abstract][Full Text] [Related]
17. Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.
Slayden RA; Lee RE; Armour JW; Cooper AM; Orme IM; Brennan PJ; Besra GS
Antimicrob Agents Chemother; 1996 Dec; 40(12):2813-9. PubMed ID: 9124847
[TBL] [Abstract][Full Text] [Related]
18. Antituberculosis Activity of the Antimalaria Cytochrome
Chong SMS; Manimekalai MSS; Sarathy JP; Williams ZC; Harold LK; Cook GM; Dick T; Pethe K; Bates RW; Grüber G
ACS Infect Dis; 2020 Apr; 6(4):725-737. PubMed ID: 32092260
[TBL] [Abstract][Full Text] [Related]
19. Reconstitution of Protein Translation of Mycobacterium Reveals Functional Conservation and Divergence with the Gram-Negative Bacterium Escherichia coli.
Srivastava A; Asahara H; Zhang M; Zhang W; Liu H; Cui S; Jin Q; Chong S
PLoS One; 2016; 11(8):e0162020. PubMed ID: 27564552
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of mycobacterial growth by plumbagin derivatives.
Mathew R; Kruthiventi AK; Prasad JV; Kumar SP; Srinu G; Chatterji D
Chem Biol Drug Des; 2010 Jul; 76(1):34-42. PubMed ID: 20456370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
